Impact of National Centralized Drug Procurement policy on chemical pharmaceutical enterprises' R&D investment: a difference-in-differences analysis in China

被引:0
|
作者
Li, Jiaming [1 ]
Zhang, Xinyue [2 ]
Wang, Rui [1 ]
Cao, Keyao [1 ]
Wan, Luhui [1 ]
Ren, Xu [1 ]
Ding, Jinxi [1 ,3 ]
Li, Wei [1 ,3 ]
机构
[1] China Pharmaceut Univ, Sch Int Pharmaceut Business, Nanjing, Peoples R China
[2] Zhejiang Chinese Med Univ, Affiliated Hosp 2, Xinhua Hosp Zhejiang Prov, Hangzhou, Peoples R China
[3] China Pharmaceut Univ, Pharmaceut Market Access Policy Res Ctr, Nanjing, Peoples R China
关键词
National Centralized Drug Procurement policy; chemical pharmaceutical enterprise; R&D investment; influence mechanism; difference-in-difference analysis;
D O I
10.3389/fpubh.2024.1402581
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective: This study aimed to evaluate the impact of the National Centralized Drug Procurement (NCDP) policy on chemical pharmaceutical enterprises' R&D investment and provide references for improving NCDP policy design and encouraging innovation in the pharmaceutical industry. Methods: Using the panel data of 102 Shanghai and Shenzhen A-share listed enterprises from 2016 to 2022 under the chemical pharmaceutical classification of Shenwan in Wind database as the research sample, this study developed difference-in-differences (DID) models on bid-winning and bid-non-winning enterprises, respectively, to evaluate the impact of NCDP policy on their R&D investment. In addition, this study tested the heterogeneity of bid-winning enterprises based on the bid success rate, the decline of drug price, and enterprise size. Results: The NCDP policy could encourage chemical pharmaceutical companies to increase R&D investment, but the low bid success rate and excessive drug price reduction would reduce their R&D enthusiasm, especially for small- and medium-sized enterprises. Discussion: It is suggested that the NCDP policy should be further improved: first, revise the bidding rule of the NCDP policy and increase the bid success rate so that more enterprises can win bids, and second, to solve the problem of excessive drug price reduction, evaluate the rationality of bid-winning prices, and introduce a two-way selection mechanism between medical institutions and supply enterprises. Integrate pharmacoeconomic evaluation into the NCDP rules to form a benign competition among enterprises. Third, attention should be paid to supporting policies for small- and medium-sized enterprises. By increasing procurement volume, shortening payment time limits, and increasing the proportion of advance payments, enterprises' cash flow shortages can be alleviated, thus achieving fairness and inclusiveness in the implementation of the NCDP policy.
引用
下载
收藏
页数:13
相关论文
共 26 条
  • [11] Impact of Monetary Policy Uncertainty on R&D Investment Smoothing Behavior of Pharmaceutical Manufacturing Enterprises: Empirical Research Based on a Threshold Regression Model
    Yang, Jingyuan
    Wang, Ling
    Sun, Ziyuan
    Zhu, Fangming
    Guo, Yihui
    Shen, Yan
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (21)
  • [12] Government subsidies, R&D investment and innovation performance: analysis from pharmaceutical sector in China
    Xu, Jian
    Wang, Xiuhua
    Liu, Feng
    TECHNOLOGY ANALYSIS & STRATEGIC MANAGEMENT, 2021, 33 (05) : 535 - 553
  • [13] Does "National Civilized City" policy mitigate air pollution in China? A spatial Durbin difference-in-differences analysis
    Jiang, Lei
    Zhang, Zinan
    Zhang, Bo
    He, Shixiong
    BMC PUBLIC HEALTH, 2024, 24 (01)
  • [14] The Impact of China's National Essential Medicine Policy and Its Implications for Urban Outpatients: A Multivariate Difference-in-Differences Study
    Ding, Liman
    Wu, Jing
    VALUE IN HEALTH, 2017, 20 (03) : 412 - 419
  • [15] The impact of government subsidies and enterprises' R&D investment: A panel data study from renewable energy in China
    Yu, Feifei
    Guo, Yue
    Le-Nguyen, Khuong
    Barnes, Stuart J.
    Zhang, Weiting
    ENERGY POLICY, 2016, 89 : 106 - 113
  • [16] An Analysis on R&D Investment Intensity of Enterprises Ranking in "Top 500" Consistently for Five Consecutive Years in China
    Liu Biao
    Li Yuju
    Li Jiaye
    PROCEEDINGS OF THE THIRD INTERNATIONAL SYMPOSIUM - MANAGEMENT, INNOVATION & DEVELOPMENT, BKS ONE & TWO, 2016, : 390 - 395
  • [17] National pharmacare, reference-based pricing, and drug R&D: A critique of the National Forum on Health's recommendations for pharmaceutical policy
    Lindsey, R
    West, DS
    CANADIAN PUBLIC POLICY-ANALYSE DE POLITIQUES, 1999, 25 (01): : 1 - 27
  • [18] Impact of government policies on private R&D investment in agricultural biotechnology: Evidence from chemical and pesticide firms in China
    Deng, Haiyan
    Hu, Ruifa
    Pray, Carl
    Jin, Yanhong
    TECHNOLOGICAL FORECASTING AND SOCIAL CHANGE, 2019, 147 : 208 - 215
  • [19] The impact of R&D subsidies on firm innovation in different supervision situations: analysis from pharmaceutical companies in China
    Xia Yuntian
    TECHNOLOGY ANALYSIS & STRATEGIC MANAGEMENT, 2024, 36 (08) : 1792 - 1809
  • [20] The Necessity for China's Enterprises to Enhance Capability of Independent Innovation under the Rules of TPP Based on the analysis of R&D investment structure
    Guo Yuanyuan
    Cheng Liwei
    PROCEEDINGS OF THE 8TH (2016) INTERNATIONAL CONFERENCE ON FINANCIAL RISK AND CORPORATE FINANCE MANAGEMENT, 2016, : 379 - 385